IRLAB Therapeutics (Sweden) Performance
| IRLAB-A Stock | SEK 3.33 0.16 5.05% |
The company retains a Market Volatility (i.e., Beta) of -0.28, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning IRLAB Therapeutics are expected to decrease at a much lower rate. During the bear market, IRLAB Therapeutics is likely to outperform the market. At this point, IRLAB Therapeutics has a negative expected return of -0.98%. Please make sure to check out IRLAB Therapeutics' treynor ratio, skewness, rate of daily change, as well as the relationship between the value at risk and accumulation distribution , to decide if IRLAB Therapeutics performance from the past will be repeated at future time.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days IRLAB Therapeutics AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in August 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 277 M | |
| Total Cashflows From Investing Activities | -708 K |
IRLAB |
IRLAB Therapeutics Relative Risk vs. Return Landscape
If you would invest 704.00 in IRLAB Therapeutics AB on April 28, 2025 and sell it today you would lose (371.00) from holding IRLAB Therapeutics AB or give up 52.7% of portfolio value over 90 days. IRLAB Therapeutics AB is generating negative expected returns and assumes 5.9423% volatility on return distribution over the 90 days horizon. Simply put, 53% of stocks are less volatile than IRLAB, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
IRLAB Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for IRLAB Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as IRLAB Therapeutics AB, and traders can use it to determine the average amount a IRLAB Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1649
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IRLAB-A |
Estimated Market Risk
| 5.94 actual daily | 53 53% of assets are less volatile |
Expected Return
| -0.98 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average IRLAB Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of IRLAB Therapeutics by adding IRLAB Therapeutics to a well-diversified portfolio.
IRLAB Therapeutics Fundamentals Growth
IRLAB Stock prices reflect investors' perceptions of the future prospects and financial health of IRLAB Therapeutics, and IRLAB Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on IRLAB Stock performance.
| Return On Equity | -0.28 | |||
| Return On Asset | -0.15 | |||
| Profit Margin | (1.69) % | |||
| Operating Margin | (1.68) % | |||
| Current Valuation | 1.74 B | |||
| Shares Outstanding | 51.79 M | |||
| Price To Book | 6.24 X | |||
| Price To Sales | 33.49 X | |||
| Revenue | 207.78 M | |||
| EBITDA | 55.62 M | |||
| Cash And Equivalents | 401.9 M | |||
| Cash Per Share | 2.89 X | |||
| Total Debt | 3.57 M | |||
| Debt To Equity | 2.90 % | |||
| Book Value Per Share | 6.25 X | |||
| Cash Flow From Operations | 128.64 M | |||
| Earnings Per Share | 0.81 X | |||
| Total Asset | 472.45 M | |||
About IRLAB Therapeutics Performance
By analyzing IRLAB Therapeutics' fundamental ratios, stakeholders can gain valuable insights into IRLAB Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if IRLAB Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if IRLAB Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
IRLAB Therapeutics AB operates as a drug discovery and development company that provides drugs in the field of neurological and neuropsychiatric disorders. Its pipeline candidates include IRL790, a psychomotor stabilizer for the treatment of L-dopa induced dyskinesias in Parkinsons disease and Parkinson disease psychosis IRL752, a cortical enhancer for the treatment of Parkinson disease dementia and behavioral and psychological symptoms of dementia IRL626, a fast-off D2 antagonist for use in the treatment of schizophrenia P001, a cortical enhancer program for the treatment of attention disorders and IRL448IRL555, a followup Parkinsons disease program. IRLAB Therapeutics is traded on Stockholm Stock Exchange in Sweden.Things to note about IRLAB Therapeutics performance evaluation
Checking the ongoing alerts about IRLAB Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for IRLAB Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| IRLAB Therapeutics generated a negative expected return over the last 90 days | |
| IRLAB Therapeutics has high historical volatility and very poor performance | |
| About 39.0% of the company shares are held by company insiders |
- Analyzing IRLAB Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether IRLAB Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining IRLAB Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating IRLAB Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of IRLAB Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of IRLAB Therapeutics' stock. These opinions can provide insight into IRLAB Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for IRLAB Stock analysis
When running IRLAB Therapeutics' price analysis, check to measure IRLAB Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IRLAB Therapeutics is operating at the current time. Most of IRLAB Therapeutics' value examination focuses on studying past and present price action to predict the probability of IRLAB Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IRLAB Therapeutics' price. Additionally, you may evaluate how the addition of IRLAB Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |